The Use of Epidermal Growth Factor Receptor Monoclonal Antibodies in Squamous Cell Carcinoma of the Head and Neck

Table 3

Cetuximab in the palliative setting.

Study	Year	Phase	Number of Patients/agent	Response (%)/Survival (months)
Cetuximab alone
Baselga et al. [24]	2000	I	𝑛=17	SD 69
Vermorken et al. [25]	2007	II	𝑛=103	CR 0
				PR 13
				SD 33
				DCR 46
				ORR 13
Cetuximab + chemotherapy
Baselga et al. [26]	2005	II	𝑛=96; platinum therapy	CR 0
				PR 10
				SD 43
				DCR 53
				ORR 10
Herbst et al. [27]	2005	II	𝑛=131; cisplatin/paclitaxel; or cisplatin/5-FU	CR 2
				PR 12
				SD 50
				DCR 64
				ORR 13
Burtness et al. [28]	2005	III	𝑛=117; cisplatin	ORR 26 versus 10
				PFS 4.2 versus 2.7
				OS 9.2 versus 8.0
Bourhis et al. [29]	2006	I/II	𝑛=53; platinum/5-FU	CR 4
				PR 32
				SD 38
				DCR 74
				ORR 36
Vermorken et al. [30] (EXTREME)	2008	III	𝑛=442; platinum/5-FU	ORR 36 versus 20
				DCR 81 versus 60
				PFS 5.6 versus 3.3 mo*
				OS 10.1 versus 7.4 mo*

CR: complete response, PR: partial response, SD: stable disease, DCR: disease control rate (CR + PR + SD), ORR: overall response rate, PFS: progression-free survival, and OS: overall survival; *statistically significant.